Completed PHASE3 INTERVENTIONAL 1-arm NCT00957203

Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients (6002-010)

Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)

Sponsor: Kyowa Kirin Co., Ltd.

Updated 7 times since 2017 Last updated: Aug 30, 2012 Started: Oct 31, 2009 Primary completion: Sep 30, 2011 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00957203, this PHASE3 trial focuses on Parkinson's Disease and remains completed. Sponsored by Kyowa Kirin Co., Ltd., it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Aug 2019 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan